Why Edgewise Therapeutics (EWTX) Is Up 6.4% After Long-Term Sevasemten Becker Data - And What's Next

Edgewise Therapeutics recently presented long-term data from its MESA open-label extension study of investigational drug sevasemten in Becker muscular dystrophy, showing sustained stabilization of ...
Nasdaq

Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up

BOULDER, Colo., March 10, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today presented at the 2026 MDA Clinical and Scientific ...
The Florida Times-Union

Becker’s Healthcare Deploys AI-Driven Infrastructure to Transform Internal Data Operations

CHICAGO, IL, UNITED STATES, March 13, 2026 /EINPresswire.com/ — Becker’s Healthcare has introduced a new AI-driven operational system designed to dramatically ...